Loading stock data...

Biocon Limited

NSE: BIOCON BSE: BIOCON

NSE
365.20 1.15 (0.32%)

Prev Close

364.05

Open Price

364.05

Volume

1,189,379

Today Low / High

363.2 / 366.8

52 WK Low / High

291 / 406

Range

347 - 383

BSE
365.10 1.25 (0.34%)

Prev Close

363.85

Open Price

363.1

Volume

29,290

Today Low / High

363.1 / 366.8

52 WK Low / High

290.8 / 405.9

Range

347 - 383

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 365.2 (target range: 347 - 383), reflecting a change of 1.15 (0.31589%). On the BSE, it is listed at 365.1 (target range: 347 - 383), showing a change of 1.25 (0.34355%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

12 Sep 364.05 0.32%
11 Sep 364.20 -0.04%
10 Sep 366.00 -0.49%
09 Sep 364.15 0.10%
08 Sep 364.00 0.04%
05 Sep 354.00 2.74%
04 Sep 364.50 -2.10%
03 Sep 355.50 1.70%
02 Sep 353.40 0.76%
01 Sep 349.00 1.02%
29 Aug 353.25 -1.39%
28 Aug 361.00 -2.15%
26 Aug 358.95 -0.18%
25 Aug 361.15 -0.33%
22 Aug 356.35 0.88%
21 Aug 360.00 -0.63%
20 Aug 363.85 -1.21%
19 Aug 366.50 -0.72%
18 Aug 363.00 0.36%

Biocon Limited Graph

Biocon Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Biocon Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 365.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 365.10 368.75 331.88 - 405.63
372.40 297.92 - 446.88
376.05 263.24 - 488.87
Bearish Scenario 365.10 361.45 325.30 - 397.59
357.80 286.24 - 429.36
354.15 247.90 - 460.39

Overview of Biocon Limited

ISIN

INE376G01013

Industry

Biotechnology

Vol.Avg

4,555,306

Market Cap

488,257,792,000

Last Dividend

0.5

Official Website

Visit Website

IPO Date

2004-04-07

DCF Diff

-25.80

DCF

392

Financial Ratios Every Investor Needs

Stock Dividend of BIOCON

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-07-04 July 04, 25 0.5 0.5 2025-07-04 2025-08-22
2024-07-05 July 05, 24 0.5 0.5 2024-07-05 2024-08-23
2023-07-07 July 07, 23 1.5 1.5 2023-07-07 2023-09-08
2022-06-30 June 30, 22 0.5 0.5 2022-07-01 2022-08-28
2019-07-18 July 18, 19 0.5 0.5 2019-07-19 2019-08-02 2019-04-25

Stock Rating Details for BIOCON

Metric Value Recommendation
Overall Rating B- Neutral
DCF Score 4 Buy
ROE Score 3 Neutral
ROA Score 3 Neutral
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 3 Neutral

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 15,052.20 Cr 5,197.50 Cr 9,854.70 Cr 0.6547 878.80 Cr 622.10 Cr 1,331.70 Cr 1,013.30 Cr 8.46 4,471.00 Cr 0.0673
2024-03-31 14,755.70 Cr 5,582.20 Cr 9,173.50 Cr 0.6217 1,237.80 Cr 2,665.50 Cr 5,083.20 Cr 1,022.50 Cr 8.55 4,152.60 Cr 0.0693
2023-03-31 11,174.20 Cr 3,663.10 Cr 7,511.10 Cr 0.6722 613.20 Cr 265.10 Cr 1,564.30 Cr 462.70 Cr 3.88 2,596.20 Cr 0.0414
2022-03-31 8,024.80 Cr 2,723.60 Cr 5,301.20 Cr 0.6606 502.80 Cr 186.90 Cr 1,158.30 Cr 648.40 Cr 5.44 2,071.80 Cr 0.0808
2021-03-31 6,970.10 Cr 2,210.20 Cr 4,759.90 Cr 0.6829 395.00 Cr 252.90 Cr 953.90 Cr 740.50 Cr 6.24 1,919.90 Cr 0.1062

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 3,227.10 Cr 58,797.30 Cr 31,084.80 Cr 21,644.0000 Cr 18,362.00 Cr 15,134.90 Cr 4,931.10 Cr 13,414.10 Cr 0.00 Cr 336.60 Cr 869.90 Cr 14,333.8000 Cr
2024-03-31 1,233.40 Cr 56,070.70 Cr 30,795.90 Cr 19,783.7000 Cr 16,276.70 Cr 15,043.30 Cr 4,943.90 Cr 11,977.80 Cr 634.10 Cr 310.70 Cr 0.00 Cr 15,358.8000 Cr
2023-03-31 1,323.50 Cr 52,042.80 Cr 29,554.00 Cr 17,866.9000 Cr 18,018.80 Cr 16,695.30 Cr 4,243.70 Cr 10,122.60 Cr 899.00 Cr 290.10 Cr 867.30 Cr 8,510.7000 Cr
2022-03-31 662.60 Cr 20,394.00 Cr 10,924.00 Cr 8,432.5000 Cr 5,146.60 Cr 4,484.00 Cr 2,298.20 Cr 9,415.50 Cr 1,260.90 Cr 1,215.10 Cr 370.20 Cr 3,828.0000 Cr
2021-03-31 952.60 Cr 18,522.30 Cr 10,014.70 Cr 7,626.9000 Cr 4,481.10 Cr 3,528.50 Cr 1,866.60 Cr 7,964.10 Cr 1,261.50 Cr 1,025.30 Cr 882.10 Cr 4,210.1000 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 4,061.2000 Cr -234.1000 Cr -1,854.0000 Cr 1,717.9000 Cr 2,004.3000 Cr 2,923.8000 Cr -2,136.6000 Cr 1,429.4000 Cr 572.9000 Cr -82.9000 Cr -0.3000 Cr
2024-03-31 2,953.9000 Cr -1,004.5000 Cr -2,332.7000 Cr 1,022.3000 Cr -380.4000 Cr 919.5000 Cr -1,931.6000 Cr 1,022.5000 Cr -1,271.2000 Cr -203.0000 Cr -886.4000 Cr
2023-03-31 1,852.5000 Cr -14,281.8000 Cr 13,048.7000 Cr 126.2000 Cr 641.1000 Cr 1,294.8000 Cr -1,726.3000 Cr 643.0000 Cr 12,415.9000 Cr -71.8000 Cr 886.2000 Cr
2022-03-31 1,176.6000 Cr -1,699.1000 Cr 242.1000 Cr -748.2000 Cr -243.3000 Cr 653.7000 Cr -1,924.8000 Cr 771.6000 Cr 321.3000 Cr 0.0000 Cr -414.0000 Cr
2021-03-31 1,159.7000 Cr -3,624.7000 Cr 2,564.0000 Cr -586.6000 Cr 72.3000 Cr 897.0000 Cr -1,746.3000 Cr 846.2000 Cr 1,888.8000 Cr 0.0000 Cr -445.4000 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 3,910.10 Cr 1,405.10 Cr 2,505.00 Cr 0.6406 293.90 Cr 31.40 Cr 0.26 828.60 Cr 0.0080
2025-03-31 4,453.90 Cr 1,472.90 Cr 2,981.00 Cr 0.6693 641.90 Cr 344.50 Cr 2.88 1,100.55 Cr 0.0773
2024-12-31 3,773.00 Cr 1,359.30 Cr 2,413.70 Cr 0.6397 292.30 Cr 25.10 Cr 0.21 804.70 Cr 0.0067
2024-09-30 3,590.40 Cr 1,182.60 Cr 2,407.80 Cr 0.6706 265.50 Cr -16.00 Cr -0.13 743.90 Cr -0.0045
2024-06-30 3,432.90 Cr 2,311.40 Cr 1,121.50 Cr 0.3267 215.00 Cr 659.70 Cr 5.49 620.40 Cr 0.1922

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-06-30 2,905.00 Cr 3,184.00 Cr 6,089.00 Cr 5,845.00 Cr 5,756.00 Cr 18,969.00 Cr 13,629.00 Cr 61,395.00 Cr 29,397.00 Cr
2025-03-31 3,227.10 Cr 1,697.50 Cr 5,023.40 Cr 5,584.30 Cr 4,931.10 Cr 16,286.20 Cr 13,414.10 Cr 58,797.30 Cr 31,084.80 Cr
2024-12-31 2,569.00 Cr 549.00 Cr 3,118.00 Cr 6,365.00 Cr 5,052.00 Cr 15,651.00 Cr 0.00 Cr 58,013.00 Cr 30,448.00 Cr
2024-09-30 1,687.70 Cr 555.90 Cr 2,650.30 Cr 6,129.20 Cr 4,965.10 Cr 15,153.50 Cr 12,453.40 Cr 57,127.90 Cr 30,407.90 Cr
2024-06-30 1,919.00 Cr 814.00 Cr 2,574.00 Cr 0.00 Cr 5,037.00 Cr 2,574.00 Cr 12,133.00 Cr 55,671.00 Cr -25,274.80 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-03-31 344.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 25.10 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 -16.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 659.70 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 135.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
2019-06-12 June 12, 19 2:1
2017-06-15 June 15, 17 3:1
2008-09-11 September 11, 08 2:1

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹365.20 ₹488,257,792,000.00 ₹1,189,379.00
Piramal Pharma Limited PPLPHARMA ₹200.67 ₹266,740,236,294.00 ₹1,721,652.00
Syngene International Limited SYNGENE ₹664.15 ₹266,566,494,350.00 ₹999,194.00
Concord Biotech Limited CONCORDBIO ₹1,639.00 ₹171,465,951,800.00 ₹133,009.00
Blue Jet Healthcare Limited BLUEJET ₹716.95 ₹124,366,032,869.00 ₹2,386,758.00
Jubilant Ingrevia Limited JUBLINGREA ₹708.35 ₹112,826,696,350.00 ₹181,175.00
Supriya Lifescience Limited SUPRIYA ₹647.60 ₹52,120,661,280.00 ₹75,601.00
Zota Health Care Limited ZOTA ₹1,522.40 ₹45,835,505,760.00 ₹97,581.00
Dishman Carbogen Amcis Limited DCAL ₹263.75 ₹41,351,516,250.00 ₹158,149.00
Panacea Biotec Limited PANACEABIO ₹425.30 ₹26,049,922,710.00 ₹59,798.00

Key Executives

Group Chief Information Officer
Mr. Atanu Roy

Gender: male

Year Born:

Global Head of Communications & Corporate Brand
Ms. Seema Shah Ahuja BA, MBA

Gender: female

Year Born: 1966

Founder & Executive Chairperson
Dr. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc.

Gender: Not Specified

Year Born: 1953

Head of Operations
Mr. Arun Gupta

Gender: male

Year Born:

Commercial Head of Biocon Global Generics
Mr. Abhijit Zutshi

Gender: male

Year Born:

MD, Chief Executive Officer & Director
Mr. Siddharth Mittal BCom, CA, CPA

Gender: male

Year Born: 1978

Head of Investor Relations
Mr. Saurabh Paliwal

Gender: male

Year Born:

Head of Human Resources
Ms. Maninder Kapoor Puri

Gender: female

Year Born: 1973

Chief Financial Officer
Mr. Mukesh Kamath

Gender: male

Year Born:

Chief Commercial Officer, U.S. & Portfolio Strategy & Business Dev, Adv mkts of Biosimilars Business
Mr. Paul Vazhayil Thomas

Gender: male

Year Born: 1973

FAQs about Biocon Limited

Who is the CEO of the company?

The CEO is Siddharth Mittal BCom, CA, CPA.

What is the current market price of the stock?

The current price is ₹365.20.

What is the 52-week price range?

The range is ₹291-406.

What is the market capitalization of the company?

The market capitalization is ₹48,825.78 crores.

What is the dividend yield?

The dividend yield is 0.14%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 114.56.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Biocon Limited (ISIN: INE376G01013) is a leading Biotechnology in India. With a market capitalization of ₹48,825.78 crores and an average daily volume of 4,555,306 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.5.